 |
A Chat with AnatAuthor: ApotheCom
"A Chat with Anat" is a series for ophthalmologists who are interested in improving delivery of care for patients living with retinal disease, and for those interested in clinically-challenging situations or controversies in care. Im Professor Anat Loewenstein, Chair of the Department of Ophthalmology at Tel Aviv Sourasky Medical Centre in Israel, and Professor of Ophthalmology and Vice Dean at Tel Aviv University. For each episode, I will be joined by internationally renowned colleagues to discuss these important topics. This podcast series is sponsored and organized by Bayer and produced by ApotheCom.This podcast series is produced and funded by Bayer. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise. This is not intended for UK audiences. Language: en-gb Genres: Life Sciences, Science Contact email: Get it Feed URL: Get it iTunes ID: Get it |
Listen Now...
Revolutionizing holistic patient care: Innovations and technologies
Wednesday, 8 January, 2025
My guest for this special episode is Dr. John Kitchens, Vitreoretinal Surgeon with Retina Associates of Kentucky in the USA. In this episode, John and I explore the importance of holistic patient care. We also highlight the latest advances in home monitoring technologies in retinal disease, and how artificial intelligence (AI) can be used to aid in disease monitoring and optimization of clinic organization. To learn more about the current status of AI in screening, diagnosing and managing retinal diseases, read the Vision Academy Viewpoint, and the Vision Academy retinal expert consensuses by clicking here or here. For more information about patient-focused care, visit the nAMD Barometer and DR Barometer websites. If you enjoyed this episode, SUBSCRIBE to “A Chat with Anat” to make sure you never miss an episode! Speaker disclosures:Professor Anat Loewenstein- Consultant: Consultant for 4DMT, Abbvie, Alkeus, Annexon, Apellis, Astellas, Bayer health care, Beyeonics, Eyepoint, J & J, NotalVision, Novartis, Ocular Therapeutics, Ocuphire Pharma, Ocuterra, Oculis, Opthea, Oxurion, Roche, Syneos.Dr. John Kitchens - Consultant: Alcon, Allergan, Alimera, Apellis, Astellas, Bayer, Biogen, Bausch + Lomb, Genentech, Kodiak Bioscience, Notal Vision, Optos, Oculus, Outlook, Regeneron, Roche, and Zeiss. Speaker: Alcon, Bayer, Genentech, and Regeneron. Owns stock in Regeneron.Further information on topics discussed in this podcast:Age-Related Eye Disease Study Research Group. A Randomized, Placebo-Controlled, Clinical Trial of High-Dose Supplementation With Vitamins C and E, Beta Carotene, and Zinc for Age-Related Macular Degeneration and Vision Loss: AREDS Report No. 8. Arch Ophthalmol. 2001;119:1417–1436.The Age-Related Eye Disease Study 2 (AREDS2) Research Group, Chew EY, SanGiovanni JP, et al. Lutein/Zeaxanthin for the Treatment of Age-Related Cataract: AREDS2 Randomized Trial Report No. 4. JAMA Ophthalmol. 2013;131:843–850. Anguita R, Ferro Desideri L, Loewenstein A, et al. The digital age in retinal practice. Int J Retina Vitreous. 2024 Sep 26;10:67. doi: 10.1186/s40942-024-00580-2. January 2025 PP-PF-OPHT-ALL-0199-1This podcast series is intended for HCPs, and is not intended for UK audiences. Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing. This podcast series is produced and funded by Bayer. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise.The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer. The activities of the Barometer Program are funded and facilitated by Bayer where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program. The Vision Academy is a group of over 100 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer.
